Efficacy and Safety of PrabotulinumtoxinA for the Treatment of Moderate to Severe Glabellar Lines: A GRADE Assessed Systematic Review and Meta-Analysis

Clicks: 9
ID: 332374
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #112 of 125 articles by views in Aesthetic Surgery Journal Open Forum

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 125 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Glabellar lines are among the earliest and most visible signs of facial aging and can convey negative emotions while diminishing quality of life. PrabotulinumtoxinA is a 900-kDa formulation of botulinum toxin type A that provides targeted neuromuscular blockade to treat dynamic wrinkles through localized muscle relaxation. Individual trials have reported encouraging results, yet pooled estimates were needed to more accurately quantify efficacy and safety. The objective of this meta-analysis was to evaluate the efficacy and safety of prabotulinumtoxinA for the treatment of glabellar lines. We searched PubMed, Cochrane CENTRAL, Scopus, Embase, and ClinicalTrials.gov through May 2026 and identified three double-blind, placebo-controlled phase III randomized controlled trials evaluating a 20 U dose of prabotulinumtoxinA versus placebo; three additional studies were included for qualitative safety analysis. In pooled random-effects analyses, prabotulinumtoxinA significantly increased the likelihood of achieving none-or-mild glabellar line severity scores (GLS score 0/1) at Day 30 (RR = 19.24, 95% CI 12.08–30.64; p < 0.01), demonstrated early treatment response at Day 2 (≥1-point improvement in GLS score: RR = 3.61, 95% CI 2.52–5.19; p < 0.01), and showed greater sustainability through Day 150 (RR = 3.47, 95% CI 2.13–5.65; p < 0.01). Safety outcomes, including treatment-emergent adverse events (TEAEs) and specific safety endpoints, were comparable to placebo, with no significant differences. PrabotulinumtoxinA was well-tolerated and produced substantial and sustained improvement of glabellar lines. Further large-scale, long-term trials are needed to establish its durability and long-term safety profile.
Reference Key
openalex_W7221824338 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Zain Ul Abideen Shahid, Muhammad Hassan, Syeda Azra Batool, Mehak Faisal, Sameer Tariq, Syeda Huda Fatima, Muhammad Hussain, Syeda Jazilah Faisal, Ghulam Taha Khan, Aleena Batool, Syed Hadi Raza Rizvi, Murtaza Aslam, Talha Aamir, Huzaifa Salman Madni, Saad Ashraf, Ibrahim Nagmeldin Hassan
Are you one of these authors? Claim your profile
Journal Aesthetic Surgery Journal Open Forum
Year 2026
DOI
10.1093/asjof/ojag202
URL
https://doi.org/10.1093/asjof/ojag202
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.